Skip to main content
Cancer Genetics settles failed merger with NovellusDx
10/28/2019

Cancer Genetics has settled its failed merger deal with NovellusDx, paying $1.1 million in cash and $450,000 over nine months. The firm also received $6 million from Interpace Diagnostics related to the recent $23.5 million sale of its biopharma business to Interpace.

Full Story: